(MedPage Today) — As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent American Society of Clinical…
Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/116164
Author :
Publish date : 2025-06-20 15:06:00
Copyright for syndicated content belongs to the linked Source.
